Background:Urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-producing organisms limit oral treatment options. Nitrofurantoin is frequently used, but regional data on its activity against ESBL-producing Escherichia coli (ESBL-EC) and Klebsiella pneumoniae (ESBL-KP) are lacking in Saudi Arabia. This study aimed to determine the 90-day failure rate of oral nitrofurantoin in treating ESBL-UTIs and explore secondary outcomes. Methods:This was a retrospective cohort study conducted at a tertiary hospital in Riyadh, Saudi Arabia. The target population was adult ED patients, discharged on oral nitrofurantoin for UTIs caused by ESBL-EC or ESBL-KP, between February 2021 and June 2024. We aimed to identify the failure rate of oral nitrofurantoin in this population. Treatment failure was defined as any ESBL-positive urine culture within 90 days of treatment initiation. Results:Among 13,421 UTI cases, 347 (2.6%) were ESBL-positive; 41 received oral nitrofurantoin, and 18 met the final inclusion criteria. The 90-day recurrence rate was 22.2% (4/18), with 77.8% having no early recurrence. Three patients had recurrence between 90–180 days. Half of all nitrofurantoin-treated patients were later hospitalized, with severe cases requiring ICU. Conclusion:Nitrofurantoin showed a 22% failure rate in treating ESBL-UTIs, yet remained effective in most cases, especially those involving ESBL-EC. Given its accessibility, nitrofurantoin remains a viable option but requires close follow-up. Larger studies are needed to refine its role in ESBL-UTI management.
Alrehaili et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: